Related Experiment Video

Updated: Aug 13, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Novel anticoagulants for stroke prevention in patients with atrial fibrillation

A Jalota1, T M Scarabelli, L Saravolatz

  • 1Mount Sinai Medical Center, New York, NY, USA.

Cardiovascular Drugs and Therapy
|May 21, 2014
PubMed

Insights

New oral anticoagulants (NOACs) offer a safer and more effective alternative to warfarin for stroke prevention in atrial fibrillation (AF) patients. These novel drugs do not require routine monitoring and have predictable effects, reducing AF-related strokes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Atrial fibrillation (AF) is a common arrhythmia linked to stroke risk.
  • Vitamin K antagonists (VKAs) like warfarin were the standard for stroke prevention in non-valvular AF.
  • Newer oral anticoagulants (NOACs) offer alternatives with improved properties.

Purpose of the Study:

  • To review the efficacy and safety of NOACs compared to VKAs for stroke prevention in non-valvular AF.
  • To highlight the pharmacological advantages of NOACs over VKAs.
  • To inform clinical guideline evolution and practice regarding NOAC use.

Main Methods:

  • Review of Phase III clinical trials comparing NOACs (dabigatran, edoxaban, rivaroxaban, apixaban) with warfarin.
  • Analysis of pharmacological properties, including monitoring requirements, onset of action, and drug interactions.
  • Evaluation of efficacy and safety data for stroke prevention in non-valvular AF patients.

Main Results:

  • NOACs demonstrated at least equivalent efficacy and safety to warfarin in Phase III trials.
  • NOACs do not require routine INR monitoring, unlike VKAs.
  • NOACs exhibit rapid action, stable anticoagulant effects, and fewer drug interactions.

Conclusions:

  • NOACs represent a significant advancement in stroke prevention for non-valvular AF.
  • Updated clinical guidelines incorporating NOACs are expected to reduce AF-related stroke incidence.
  • Understanding NOACs' distinct pharmacological profiles is crucial for safe and effective clinical application.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...